Loading…
Artivion, Inc. is projected to rise to $24.14 by 2027, a +6% move from its current price of $22.76. AORT is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $22.18 | $22.77 | $23.38 | +0.03% |
| May 30 | $21.94 | $22.78 | $23.64 | +0.07% |
| May 31 | $21.77 | $22.78 | $23.85 | +0.10% |
| Jun 1 | $21.62 | $22.79 | $24.03 | +0.14% |
| Jun 2 | $21.49 | $22.80 | $24.18 | +0.17% |
| Jun 3 | $21.38 | $22.81 | $24.33 | +0.21% |
| Jun 4 | $21.28 | $22.82 | $24.46 | +0.24% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $21.28 | $22.82 | $24.46 | +0.24% |
| Week 2 | $20.72 | $22.87 | $25.24 | +0.49% |
| Week 3 | $20.32 | $22.93 | $25.87 | +0.74% |
| Week 4 | $19.99 | $22.98 | $26.42 | +0.98% |
| Week 5 | $19.71 | $23.04 | $26.93 | +1.23% |
| Week 6 | $19.47 | $23.10 | $27.40 | +1.48% |
| Week 7 | $19.25 | $23.15 | $27.84 | +1.72% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers On-X prosthetic aortic and mitral heart valves; On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures; pyrolytic carbon coating services; E-vita Open NEO, a hybrid stent graft; Arcevo, an LSA hybrid stent graft system; AMDS hybrid prosthesis; and NEXUS ONE, an endovascular stent graft system.
It also provides NEXUS DUO, an aortic arch system; NEXUS TRE, a custom-made three branch graft; E-vita thoracic 3G, a stent graft system; E-xtra Design Engineering, a range of stent graft systems for the treatment of aortic vascular diseases, such as TAAA and Artivex; E-nside, a multibranch stent graft system; E-tegra, an AAA stent graft system; E-ventus BX and Tuva BX balloon-expandable peripheral stent grafts; and E-liac, a stent graft used to treat aneurysmal iliac arteries. In addition, the company offers synthetic vascular grafts that are used in open aortic and peripheral vascular surgical procedures; BioGlue, a surgical sealant; CryoValve SG pulmonary heart valve; CryoPatch SG pulmonary cardiac patch; SynerGraft, a decellularization technology; vascular preservation services; and PhotoFix, a bovine pericardial patch fixated. It markets its products and preservation services primarily to physicians through a direct sales team to hospitals and other healthcare facilities.
The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.
Artivion, Inc. trades in the Healthcare sector and is currently priced at $22.46 per share, with a market cap of $1.09B and a market-rank of 2475. The price outlook, based on year-by-year forecasts, shows a path from a 2026 average of $22.46 toward higher targets later in the period, including $32.68 by 2030 and $118.70 by 2050, with a maximum forecast of $218.47 in 2050.
The 2026 forecast expects an average price of $22.46, with a 2026 min of $22.23 and a 2026 max of $29.15, and a neutral sentiment for that year.
A major floor 50.1% below — a decisive break under it would weaken the trend.
Price is testing support right now (2.3% away) — a key level to hold.
The nearest ceiling, 70.5% above — a clean break opens room to run.
A major ceiling 95.5% above — clearing it would confirm fresh momentum.
Key AORT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of AORT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $22.77 | Sell | $22.91 | Sell |
| MA 10 | $22.83 | Sell | $23.86 | Sell |
| MA 20 | $27.44 | Sell | $26.58 | Sell |
| MA 50 | $32.85 | Sell | $31.36 | Sell |
| MA 100 | $36.51 | Sell | $34.83 | Sell |
| MA 200 | $40.14 | Sell | $36.22 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 28.32 | Buy |
| Stoch RSI (14) | 32.71 | Neutral |
| CCI (20) | -55.58 | Neutral |
| Williams %R (14) | -95.98 | Info |
| MACD (12,26,9) | -0.13 | Sell |
| ROC (12) | -10.43 | Sell |
| Bollinger %B (20,2) | 0.30 | Neutral |
| Stochastic %K (14) | 4.02 | Buy |
| TRIX (15) | -1.48 | Sell |
| Awesome (5,34) | -8.76 | Sell |
| Ultimate (7,14,28) | 37.38 | Neutral |
| Momentum (10) | -0.34 | Sell |
| Aroon Osc (25) | -52.00 | Sell |
| Hull MA (9) | 22.75 | Buy |
| ADX (14) | 34.94 | Sell |
| ATR (14) | 0.95 | Info |
Technical snapshot for the next 30 days shows Neutral sentiment. The RSI(14) is 30, and the 50-day simple moving average is $33.41 while the 200-day simple moving average is $40.28. The stock’s near-term support is at $22.23 and resistance at $38.80. The 30-day price range runs from $18.81 to $26.82, reflecting modest volatility in the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $22.23 | $22.76 | $29.53 | 0% | Neutral | |
| $19.21 | $24.14 | $32.09 | +6% | Neutral | |
| $18.99 | $24.49 | $33.71 | +8% | Neutral | |
| $21.07 | $27.78 | $39.30 | +22% | Bullish | |
| $24.49 | $32.92 | $47.67 | +45% | Bullish | |
| $26.94 | $36.85 | $54.46 | +62% | Bullish | |
| $26.49 | $36.84 | $55.45 | +62% | Bullish | |
| $25.61 | $36.18 | $55.36 | +59% | Bullish | |
| $27.94 | $40.05 | $62.23 | +76% | Bullish | |
| $28.87 | $41.96 | $66.14 | +84% | Bullish | |
| $38.07 | $58.99 | $98.71 | +159% | Bullish | |
| $70.08 | $121.13 | $221.22 | +432% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $22.23 | $22.76 | $26.68 | +0.00% |
| June 2026 | $19.65 | $23.05 | $27.68 | +1.29% |
| July 2026 | $19.86 | $23.50 | $28.58 | +1.92% |
| August 2026 | $19.34 | $23.03 | $28.30 | -1.98% |
| September 2026 | $19.05 | $22.80 | $28.25 | -0.99% |
| October 2026 | $19.55 | $23.52 | $29.35 | +3.13% |
| November 2026 | $19.71 | $23.80 | $29.90 | +1.22% |
| December 2026 | $19.27 | $23.37 | $29.53 | -1.82% |
Click any year to see its month-by-month AORT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The AORT price prediction for 2026 points to an average of $22.76 (low $22.23, high $29.53) — a potential gain of 0% on today's $22.76. A consolidation phase looks the most probable path here.
In 2027, AORT is projected to trade between $19.21 and $32.09, averaging $24.14 — a potential gain of +6% from today's $22.76. That is up +6% on the projected 2026 average. Price action looks broadly range-bound.
Artivion, Inc.'s 2028 outlook centres on $24.49, within a $18.99 to $33.71 range. That is up +1% on the projected 2027 average. That marks a +8% change versus current levels. A consolidation phase looks the most probable path here.
By 2029, AORT could reach as high as $39.30, with a base case around $27.78 and support toward $21.07 — roughly +22% from $22.76. Momentum favours further upside here.
Expect AORT to range from $24.49 to $47.67 through 2030. The $32.92 average target implies a +45% move from current prices. That is up +18% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The AORT price prediction for 2031 points to an average of $36.85 (low $26.94, high $54.46) — a potential gain of +62% on today's $22.76. Momentum favours further upside here.
In 2032, AORT is projected to trade between $26.49 and $55.45, averaging $36.84 — a potential gain of +62% from today's $22.76. That is 0% versus the projected 2031 average. Buyers look set to stay in control over this stretch.
Artivion, Inc.'s 2033 outlook centres on $36.18, within a $25.61 to $55.36 range. That is -2% versus the projected 2032 average. That marks a +59% change versus current levels. Momentum favours further upside here.
By 2034, AORT could reach as high as $62.23, with a base case around $40.05 and support toward $27.94 — roughly +76% from $22.76. Buyers look set to stay in control over this stretch.
Expect AORT to range from $28.87 to $66.14 through 2035. The $41.96 average target implies a +84% move from current prices. That is up +5% on the projected 2034 average. Momentum favours further upside here.
The AORT price prediction for 2040 points to an average of $58.99 (low $38.07, high $98.71) — a potential gain of +159% on today's $22.76. Buyers look set to stay in control over this stretch.
In 2050, AORT is projected to trade between $70.08 and $221.22, averaging $121.13 — a potential gain of +432% from today's $22.76. That is up +105% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in AORT today (≈ 43.936731 AORT) could be worth
$5,322.24
+$4,322.24 (+432%) by 2050 · US Dollar
Based on the average projected AORT price of $121.13 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in AORTwould be worth at today's price.
$1,000 invested in AORT on May 27, 2025 (≈ 34.234852 AORT) would be worth
$779.19
-$220.81 (-22.1%) today · 0.78× · US Dollar
Based on a AORT entry price of $29.21 vs. today's $22.76.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $22.67 | $1,003.97 | +0.4% |
| 1 month ago | $37.03 | $614.64 | -38.5% |
| 3 months ago | $38.08 | $597.69 | -40.2% |
| 6 months ago | $46.66 | $487.78 | -51.2% |
| 1 year ago | $29.21 | $779.19 | -22.1% |
| All time (5.0y) ago | $29.39 | $774.41 | -22.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our AORT forecast.
Our base-case forecast reaches $46.00 around 2040.
Implied market cap at $46.00: $2.23B
The multi-year forecast depicts a bullish trajectory beginning in the late 2020s and extending through 2050. In 2026 the average price is $22.46 with a 0% ROI, followed by rising averages and higher upside in subsequent years. By 2030 the average is $32.68 with a 45.5% ROI, and by 2040 the average surges to $57.51 with a 156.1% ROI.
The 2050 forecast shows an average of $118.70 with a 428.5% ROI, and the 2050 maximum price target of $218.47. Sentiment shifts to BULLISH from 2029 onward, indicating growing upside potential and confidence in higher price targets over the long term, albeit with inherent uncertainty and no guarantees.
Tap a question to reveal the answer.
The 2030 forecast lists a min of $24.22, an average of $32.68, and a max of $47.53, with a 45.5% ROI and a BULLISH sentiment.
Forecasts show the average price rising to $32.68 by 2030 and to $118.70 by 2050, with a peak max of $218.47 and ROI up to 428.5%. The outlook turns from Neutral to Bullish in later years, but these are estimates, not guarantees.
Yes. The year-by-year targets show a path to higher prices, with the 2040 max at $96.87 and the 2050 max at $218.47, meaning $100 could be reached by 2050 according to the forecast.
Current price is $22.46 and market cap is $1.09B.
The 30-day range is $18.81 to $26.82, with a current sentiment of Neutral. Support is at $22.23 and resistance at $38.80, the RSI(14) is 30, and the SMA50 is $33.41 while the SMA200 is $40.28.
Artivion, Inc. Community Discussion
0Share your Artivion, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.